Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
sub-chronic toxicity: dermal
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
4 (not assignable)

Data source

Reference
Reference Type:
other: study report
Title:
European Union Risk Assessment Report : ETHYL ACETOACETATE
Author:
EU Report
Year:
2002
Bibliographic source:
European Union risk assessment report (Ethyl acetoacetate) Vol:13 (2002) p98

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
other:
Principles of method if other than guideline:
Data is from European Union Risk assesment Report.
GLP compliance:
not specified

Test material

Constituent 1
Chemical structure
Reference substance name:
Ethyl acetoacetate
EC Number:
205-516-1
EC Name:
Ethyl acetoacetate
Cas Number:
141-97-9
Molecular formula:
C6H10O3
IUPAC Name:
ethyl 3-oxobutanoate

Test animals

Species:
other: human
Sex:
not specified

Administration / exposure

Type of coverage:
not specified
Vehicle:
not specified
Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
28 days
Frequency of treatment:
daily

Results and discussion

Effect levels

Dose descriptor:
dose level:
Effect level:
420 other: mg/day
Based on:
test mat.
Sex:
not specified
Basis for effect level:
other: It suggests that systemic health risks due to repeated dermal exposure are not expected
Remarks on result:
other: not specified

Target system / organ toxicity

Critical effects observed:
not specified
System:
other: not specified
Organ:
not specified
Treatment related:
not specified
Dose response relationship:
not specified
Relevant for humans:
not specified

Applicant's summary and conclusion

Conclusions:
In a study on ethyl acetoacetate, repeated dermal exposure of 420 mg/day suggested that systemic health risks due to repeated dermal exposure are not expected.
Executive summary:

In a study on ethyl acetoacetate, repeated dermal exposure of 420 mg/day suggested that systemic health risks due to repeated dermal exposure are not expected.